Project Oncology-logo

Project Oncology

ReachMD

Project Onology is a CME series focusing on a wide array of oncology topics designed to educate and enlighten practitioners on late-breaking discoveries, novel treatment options, evolving methods of patient management, and more. It will focus on providing cutting-edge updates on the biology, diagnosis, and multidisciplinary management, as well as increase the understanding of evidence-based recommendations to achieve optimal patient outcomes.

Project Onology is a CME series focusing on a wide array of oncology topics designed to educate and enlighten practitioners on late-breaking discoveries, novel treatment options, evolving methods of patient management, and more. It will focus on providing cutting-edge updates on the biology, diagnosis, and multidisciplinary management, as well as increase the understanding of evidence-based recommendations to achieve optimal patient outcomes.
More Information

Location:

Fort Washington, PA

Networks:

ReachMD

Description:

Project Onology is a CME series focusing on a wide array of oncology topics designed to educate and enlighten practitioners on late-breaking discoveries, novel treatment options, evolving methods of patient management, and more. It will focus on providing cutting-edge updates on the biology, diagnosis, and multidisciplinary management, as well as increase the understanding of evidence-based recommendations to achieve optimal patient outcomes.

Language:

English


Episodes

Small Molecules in Immuno-oncology: Revolutionizing Cancer Treatment

6/5/2018
More
Get a closer look at the newest development in cancer immunotherapy: the bifunctional fusion protein. Could this small but mighty protein designed to block two signaling pathways used by tumor cells to escape immune system control be the key to managing both tumor growth and metastasis? For more episodes in this series, visit ReachMD.com/IO.

Duration:00:03:59

Clinical Debates in Multiple Myeloma: Putting Evidence Into Context

5/23/2018
More
Guest: Sagar Lonial, MD, FACP The treatment armamentarium for multiple myeloma (MM) has expanded significantly in recent years, with 6 new agents or indications approved by the US Food & Drug Administration since 2015. Treatment options now include immunomodulatory drugs, proteasome inhibitors, a histone deacetylase inhibitor, and immunotherapies, making clinical decisions much more complex. Additionally, best practices and consensus guidelines, such as those from the National...

Duration:00:40:00

Immunocellular Therapies for Relapsed/Refractory Heme Malignancies: A Focus on CAR T-Cell Therapy

5/15/2018
More
Host: Robert Mocharnuk, MD Guest: Jae Park, MD The treatment of relapsed or refractory leukemias and lymphomas continues to be challenging, often characterized by limited therapeutic options and poor outcomes. Effective new therapies are needed for these patients. Chimeric antigen receptor (CAR) T-cell therapy represents a radical departure from current treatments by simultaneously being cell therapy, gene therapy, and immunotherapy. It promises to revolutionize the treatment of multiple...

Duration:00:15:00

Pathways in Oncology: Tools to Assure Quality Care

5/7/2018
More
Host: Stephen Edge, MD, FACS, FASCO In this segment, Dr. Edge discusses the benefits of using clinical oncology pathways in practice as well as their optimal use for patients. Also discussed will be how to best select the primary choice for treatment when using clinical oncology pathways. This activity is part of a series of in-depth discussions with oncology thought leaders at the Roswell Park Cancer Institute in Buffalo, New York targeting primary care and family physicians. This series...

Duration:00:18:30

Adnexal Mass Management: Risk Stratification and Management Practice for Best Patient Outcomes

2/28/2018
More
Host: Renée Simone Yolanda Allen, MD, MHSc., FACOG Guest: Burton S. Brodsky, MD, FACOG Low awareness of women’s risk factors and symptoms for ovarian cancer, compounded by common use of diagnostic laboratory tests that are less sensitive and not specifically approved for assessing the risk of malignant adnexal mass, are the most important reasons that the great majority of women with ovarian cancer are only diagnosed in late stage disease, when prognosis is far worse. In this CME...

Duration:00:14:59

Not Quite a Cancer Vaccine: Selling HPV and Cervical Cancer

2/19/2018
More
Host: Brian P. McDonough, MD, FAAFP Human papillomavirus (HPV) infection remains one of the most common sexually transmitted infections in both females and males, with about 9 in 10 people contracting HPV at some point in their lives. Host Dr. Brian McDonough is joined by Samantha Gottlieb, medical anthropologist and author of Not Quite a Cancer Vaccine: Selling HPV and Cervical Cancer. They explore the history of Gardasil, a vaccine developed for HPV but marketed primarily as a cervical...

Duration:00:14:59

Antibody-Drug Conjugates in Glioblastoma Multiforme: Finding Ways Forward

1/25/2018
More
Host: John J. Russell, MD Guest: David A. Reardon, MD Glioblastoma Multiforme (GBM) is the most common and most malignant of all glial tumors. These tumors present a challenge to the team managing the patient, as there is no curative treatment; the goal is to find the best approach and optimal role for each team member. There are a variety of treatment options, which include surgery (resection), radiotherapy, and chemotherapy. The prognosis for these patients is measured in years with...

Duration:00:13:29

Pancreatic Cancer: Associated Signs, Symptoms, Risk Factors and Treatment Approaches

5/23/2017
More
Host: Jennifer Caudle, DO Guest: Major Kenneth Lee, IV, MD, PhD Though a relatively rare disease, pancreatic cancer remains at the forefront of clinical discussion due to its highly aggressive nature. Dr. Major Kenneth Lee, Assistant Professor of Surgery at Penn Medicine, estimates that pancreatic cancer will become the number 2 cause of cancer death by the year 2020. This projected rise in mortality is largely due to the need for better advancement in treatment options. Join host Dr....

Duration:00:17:59

Highlights from ASCO 2015: The Emerging Potential of Immunotherapeutic Appr

6/22/2015
More
Host: Anthony Alessi, MD Guest: Keith Flaherty, MD The American Society of Clinical Oncology (ASCO) held its 2015 annual congress to highlight and present new data on some of the latest and most exciting discoveries in cancer research. This year’s meeting theme is – “Illumination amp; Innovation: Transforming Data into Learning.” Join us as Dr. Keith Flaherty, who attended ASCO 2015, gives us an update on some of the exciting data presented on the emerging potential of immunotherapeutic...

Duration:00:16:59